89Zr/177Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics - PubMed
8 hours ago
- #radioimmunoconjugates
- #theranostics
- #SORT1
- Sortilin (SORT1) is a receptor overexpressed in multiple cancers, making it a promising target for theranostics.
- Researchers developed [89Zr]Zr-DFO-latozinemab and [177Lu]Lu-DOTA-latozinemab as SORT1-targeted radioimmunoconjugates.
- SORT1 is significantly upregulated in melanoma, with high expression confirmed via transcriptional analyses and tissue microarray.
- The conjugates maintained picomolar affinity and demonstrated high internalization.
- [89Zr]Zr-DFO-latozinemab enabled high-contrast PET imaging, peaking at 72 hours in HT-1080-SORT1 models.
- [177Lu]Lu-DOTA-latozinemab showed prolonged tumor accumulation and favorable tumor-to-blood ratios in SK-MEL-28 xenografts.
- Therapeutic doses of [177Lu]Lu-DOTA-latozinemab significantly suppressed tumor growth by inducing DNA damage.
- This study presents the first SORT1-directed theranostic pair with high specificity and therapeutic potential.